Antonio Tito Fojo, MD

Closed
Call
Website

Photos

161 Fort Washington Ave Fl 9
New York, NY 10032
+1 (212) 305-5098
https://doctors.columbia.edu
Dr. Fojo received his MD and PhD from the University of Miami and completed internal medicine training at Washington University School of Medicine / Barnes Hospital. He joined the National Cancer Institute in 1982 as a Clinical Associate in the Medicine Branch and after training with Drs. Ira Pastan and Michael Gottesman, became a Principal Investigator in the Medicine Branch of the National Cancer Institute. As a Principal Investigator he went on to establish a highly successful translational clinical program that began by exploring agents to reverse drug resistance, continued with work on the optimal use of Taxol®, and the development of novel microtubule-targeting agents and has focused on the development of therapies for endocrine and neuroendocrine cancers. Dr. Fojo has expertise in the management of patients with adrenocortical cancer, malignant pheochromocytoma and other neuroendocrine malignancies, and thyroid cancer. These cancers also comprise areas of very active basic science interest given their unique properties and the possibilities to target such cancers more precisely. The ultimate goal is to develop novel therapies for these often very refractory cancers so that there will be additional options available for treatment for patients with these cancers. Ongoing laboratory efforts are focused on developing such novel therapies to treat patients with adrenal cancer, pheochromocytoma and a spectrum of neuroendocrine tumors. In the laboratory Dr. Fojo has also worked to understand the molecular basis of drug resistance, and was involved in the original work relating to several ABC transporters. Additionally, his laboratory originally identified rearrangements involving the MDR-1 gene as a novel mechanism of drug resistance in several cancers, a molecular event recently demonstrated as very important in ovarian cancer. He has also been very involved in research on microtubule-targeting agents, helping to establish as a novel paradigm the interference with microtubule trafficking, rather than mitosis, for the mechanism of action for these important drugs. In addition to his clinical expertise Dr. Fojo has been very interested in the design, conduct and interpretation of oncology clinical trials and in collaboration with Wilfred Stein, PhD and Susan Bates, MD has helped to pioneer a novel method of analysis that dissects rates of tumor growth and regression as concurrent events. Related to this he has also written extensively about the cost of cancer therapeutics, the magnitude of the problem and how this might be addressed. Dr. Fojo served as Program Director for the Medical Oncology Fellowship Program at the National Cancer Institute, the largest fellowship program in the NIH and one of the largest medical oncology programs in the United States. Over the years Dr. Fojo has helped to train more than 350 medical oncologists.
Click or call for more information

Also at this address

Owner verified
See a problem?

You might also like

Roshni Rao, MD FACS
Internal medicine practitioners, Services, nec, nec, Psychiatrists and psychoanalysts

Roshni Rao, MD FACS

Dr. Roshni Rao, a renowned expert in breast care, is the chief of the Breast Surgery Program at NewYork-Presbyterian/Columbia University Irving Medical Center. A skilled surgeon who is passionate in her commitment to breast health and her patients, Dr. Rao has expertise in the treatment of breast cancer that has spread to the areas surrounding the breast, known as locally advanced breast cancer; in addition to breast cancer that has spread further to other parts of the body, metastatic breast cancer. Her groundbreaking research includes the positive effects of exercise for patients with breast cancer who are preparing for surgery, and the impact of ethnicity on the risk of developing triple-negative breast cancer (when the three receptors known to fuel most breast cancers; estrogen, progesterone, and the human epidermal growth factor receptor 2; are not present in the cancer tumor). Dr. Rao oversees the breast cancer surgery program at the Comprehensive Breast Center of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia, a multi-site, multi-disciplinary entity that incorporates the legacy of innovation and trust associated with the Columbia University Irving Medical Center. She collaborates closely with its team of specialists across every discipline, including radiologists, medical oncologists, radiation oncologists, plastic surgeons and other breast cancer support staff. Dr. Rao was repeatedly recognized with awards for her leadership at the University of Texas Southwestern Medical Center in Dallas, Texas, where she served as the director of the George N. Peters Center for Breast Surgery prior to joining NewYork-Presbyterian/Columbia. She was elected by her peers to be a "Best Doctor" in breast surgery every year from 2009 to 2017. Dr. Rao received her medical degree from the University of Missouri-Columbia School of Medicine. She completed a general surgery residency at Baystate Medical Center/Tufts University School of Medicine, followed by a fellowship in breast surgical oncology at the University of Texas MD Anderson Cancer Center. She is a fellow of the American College of Surgeons and a member of the Society of Surgical Oncology. She is currently the chair of the Patient Safety and Quality Committee for the American Society of Breast Surgeons. Dr. Rao serves as a reviewer for the Journal of the American Medical Association and the Annals of Surgical Oncology, and has served as a reviewer for Cancer and other journals. Her work has been published in these journals and many other surgical and oncology publications.
Gulam A. Manji, MD
Internal medicine practitioners

Gulam A. Manji, MD

Gulam Manji, M.D., Ph.D. is an Associate Professor of Medicine at Columbia University Medical Center. Dr. Manji received his M.D. degree from Ross University School of Medicine in 2009 and completed his residency in internal medicine at Albany Medical College. He then completed his fellowship in Hematology/Oncology at NewYork-Presbyterian/Columbia, where his clinical focus was on the treatment of gastrointestinal malignancies, melanoma, and sarcoma under the mentorship of Dr. Gary Schwartz, Chief of Hematology and Oncology. Dr. Manji conducts translational research with the overall goal to developing new treatments for cancer. His focus is in gastrointestinal malignancies, particularly pancreas adenocarcinoma, on which he is conducting preclinical combination immunotherapy studies on genetically engineered mice with pancreas cancer in the Olive laboratory at the Herbert Irving Comprehensive Cancer Center. The combination immunotherapy preclinical proposal received the Young Investigator Award from the American Society of Clinical Oncology-2015. The goal of these preclinical studies is to bring promising new therapies to the clinic in an early phase clinical trials Dr. Manji's research career in identifying new genes and their implication in disease has led to numerous key publications and an issued patent. Dr. Manji cares for patients with gastrointestinal malignancies, with a particular focus on pancreatic and liver cancers, and sarcomas. He is the principal investigator of an investigator-initiated multicenter clinical trial that he wrote with Dr. Gary Schwartz in sarcoma and malignant peripheral nerve sheath tumors and is responsible for clinical trials conducted in liver, bile duct, gallbladder, and pancreas cancers at Columbia University Medical Center.
S. Sunghyun Yoon, MD
Internal medicine practitioners, Psychiatrists and psychoanalysts, Services, nec, nec

S. Sunghyun Yoon, MD

Dr. S. Sunghyun Yoon is the Chief of the Division of Surgical Oncology and Vice-Chair of Surgical Oncology Research and Education in the Department of Surgery at Columbia University Irving Medical Center (CUIMC). Dr. Yoon is a national and international expert in the treatment of patients with sarcomas and other soft tissue tumors, gastric (stomach) and gastroesophageal cancers, gastrointestinal stromal tumors (GISTs), and melanoma. He also has over 18 years of experience in the treatment of other gastrointestinal and abdominal tumors, hepatobiliary tumors, neuroendocrine/adrenal tumors, lymphomas, and spleen tumors. He has been the principal investigator of several clinical trials examining novel treatment strategies and given numerous invited national and international lectures in relation to these cancers. Several of these trials have investigated the treatment of sarcomas, especially abdominal/retroperitoneal sarcomas, with advanced radiation techniques such as proton beam radiation and aggressive surgical resection to minimize local recurrence. Read More About These Treatments: https://columbiasurgery.org/conditions-and-treatments/retroperitoneal-sarcomas-and-pelvic-sarcomas Dr. Yoon was an early advocate for minimally invasive robotic surgery and has performed over 300 robotic procedures including robotic gastrectomies (stomach removal). He has one of the world’s largest experiences in performing prophylactic total gastrectomies for patients with hereditary diffuse gastric cancer (HDGC syndrome) secondary to germline CDH1 mutation. He pioneered a technique for connection of the small bowel to the esophagus after total gastrectomy that is used by former surgical trainees and colleagues throughout the country due to its extremely low leakage rate. Dr. Yoon graduated from Harvard University and received his M.D. from the University of California at San Diego. He completed his residency in general surgery at Massachusetts General Hospital and his fellowship in surgical oncology at the Memorial Sloan-Kettering Cancer Center. He was an Associate Professor of Surgery at Massachusetts General Hospital and Harvard Medical School before joining the staff at Memorial Sloan-Kettering Cancer Center in 2012. Dr. Yoon was an Attending Surgeon in the Division of Gastric and Mixed Tumors at Memorial Sloan Kettering Cancer Center and a Professor of Surgery at Weill Cornell Medical College before joining CUIMC in 2021. Dr. Yoon’s main research interests are in cancer stem cells and targeted biological agents in combination with chemotherapy and radiation therapy. His laboratory has been funded by the National Institutes of Health/National Cancer Institute for 18 years and strives to translate new research discoveries into the clinic. Dr. Yoon is also part of multi-institution research groups funded by Stand Up To Cancer and the DeGregorio Family Foundation to discover early diagnostics and new therapies for gastric cancer. His clinical and research efforts have led to over 150 original research articles, book chapters, and reviews. For a complete list of publications, please visit NCBI.
United States›New York›New York›Antonio Tito Fojo, MD

Partial Data by Infogroup (c) 2025. All rights reserved.

Yext

Partial Data by Foursquare.